HDAC9 and fatty liver disease: FOXF2 has been shown to downregulate the expression of Insulin Receptor Substrate 1 (IRS1) in adipose tissue, thereby reducing glucose uptake [27], and HDAC9 has been implicated in adipocyte hypertrophy, IR, and hepatic steatosis [27].